CN204016366U - A kind of degradable stopper - Google Patents
A kind of degradable stopper Download PDFInfo
- Publication number
- CN204016366U CN204016366U CN201420317506.0U CN201420317506U CN204016366U CN 204016366 U CN204016366 U CN 204016366U CN 201420317506 U CN201420317506 U CN 201420317506U CN 204016366 U CN204016366 U CN 204016366U
- Authority
- CN
- China
- Prior art keywords
- stopper
- silk screen
- barrier film
- column silk
- degradable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000463 material Substances 0.000 claims abstract description 35
- 230000004888 barrier function Effects 0.000 claims abstract description 24
- 230000015556 catabolic process Effects 0.000 claims abstract description 15
- 238000006731 degradation reaction Methods 0.000 claims abstract description 15
- 239000000725 suspension Substances 0.000 claims abstract description 12
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 5
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 claims description 12
- 229920001610 polycaprolactone Polymers 0.000 claims description 12
- 239000004632 polycaprolactone Substances 0.000 claims description 12
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 9
- 239000004626 polylactic acid Substances 0.000 claims description 9
- 241000790917 Dioxys <bee> Species 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 3
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 abstract description 6
- 230000007547 defect Effects 0.000 abstract description 5
- 208000007536 Thrombosis Diseases 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 229910052759 nickel Inorganic materials 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 206010000891 acute myocardial infarction Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 6
- 208000028831 congenital heart disease Diseases 0.000 description 6
- 238000010586 diagram Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 3
- 229910001000 nickel titanium Inorganic materials 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000003017 ductus arteriosus Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920004934 Dacron® Polymers 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000035478 Interatrial communication Diseases 0.000 description 1
- 208000036830 Normal foetus Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000013914 atrial heart septal defect Diseases 0.000 description 1
- 206010003664 atrial septal defect Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009954 braiding Methods 0.000 description 1
- 210000000459 calcaneus Anatomy 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- -1 poly tetrafluoroethylene Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229940058401 polytetrafluoroethylene Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
This utility model provides a kind of degradable stopper, comprise the column silk screen of the hollow made by degradation material, the two ends of described column silk screen are provided with left side and right side, one is had at least to form card along edge outwardly convex in described two end faces, the twine of described column silk screen collects formation one node respectively on left side and right side, one of them node is connected with the suspension ring made by degradation material, barrier film is provided with in described column silk screen, described barrier film is sewn in column silk screen by degradable suture, described barrier film is degradation material, preferably, described barrier film is provided with 3 ~ 5 layers, also developing materials are provided with in described stopper.This utility model can be absorbed by the body completing shutoff defect Post operation, eliminates stopper and remains in human body the hidden danger causing side effect; The untoward reaction such as human body nickel allergy, thrombosis, acute myocardial infarction simultaneously preventing stopper from causing in vivo.
Description
Technical field
This utility model relates to a kind of medical apparatus and instruments, particularly relates to a kind of degradable stopper.
Background technology
Congenital heart disease is a modal class in congenital malformation, account for 28% of various congenital malformation, congenital heart disease refers to that the anatomical structure caused due to the formation obstacle of heart and trunk or abnormal development in fetal development period is abnormal, or the passage should automatically closed after birth fails to close the situation of (belonging to normal fetus).It is generally acknowledged that First Trimester (5 ~ 8 weeks) is that heart of fetus grows most important period, congenital heart disease reason is a lot, inherited genetic factors only accounts for about 8%, account for the overwhelming majority of 92% then for environmental factors causes, as during forepart pregnant women, drug administration, infection virus, environmental pollution, x radiation x etc. all can make heart of fetus abnormal development.Especially within pregnant first 3 months, infect rubella virus, the risk that child can be made to suffer from congenital heart disease sharply increases.Current data display, congenital heart disease rate can not look down upon, and accounts for out life baby's 0.4% ~ 1%, this means China's newly-increased patients with congenital heart 15 ~ 200,000 every year.
At present, be used for the treatment of the medical apparatus and instruments of congenital heart disease mainly with the stopper of nitinol alloy wire braiding, such as atrial septal defect stopper, ventricular septal defect plugging device, patend ductus arteriosus occluder, is used for the treatment of the vascular plug stopper of peripheral blood vessel.These stoppers generally comprise the choked flow film in nitinol alloy wire support, left and right card and nitinol alloy wire support, and choked flow film is generally dacron polyester film PET, poly tetrafluoroethylene PTFE, polyurethane PU or PVAC polyvinylalcohol.The stopper each several part material used at present is non-degradable material, and they can retain throughout one's life in vivo.
In China, stopper employs many decades, and show good curative effect, but the generation of complication is still very important, comprise that stopper comes off, the damage of thrombosis, valve, residual shunt, haemolysis, proarrhythmia, nickel are irritated, and the lifelong indwelling of metal is in body, still Data support is lacked to the long-range safety of human body, particularly to child, their heart is also in continuous growth, and the impact of the stopper in their body on them is gone back neither one long term follow-up data and can be proved.Most importantly, when stopper surface is by complete endothelialization, after defect is repaired by body autologous tissue, necessity that stopper is not retained completely in vivo, therefore, desirable stopper should be for heart self reparation provides one interim " bridge ", degraded by body after finishing the work, defect is repaired by autologous tissue completely, and the long term complication and potential safety hazard avoiding metal to retain in body bringing, therefore need a kind of stopper that can degrade.
Utility model content
The technical problems to be solved in the utility model be to provide a kind of complete heart shutoff work after the stopper that can automatically degrade, to overcome the above-mentioned defect of prior art.
In order to solve the problems of the technologies described above, this utility model adopts following technical scheme: a kind of degradable stopper, comprise the column silk screen of the hollow made by degradation material, the two ends of described column silk screen are provided with left side and right side, one is had at least to form card along edge outwardly convex in described two end faces, the twine of described column silk screen collects formation one node respectively on left side and right side, one of them node is connected with the suspension ring made by degradation material, barrier film is provided with in described column silk screen, described barrier film is sewn in column silk screen by degradable suture, described barrier film is degradation material, also developing materials are provided with in described stopper.
Preferably, the developing powder added in column silk screen when described developing materials are metal or the production of the good biocompatibility be coated in barrier film.
Preferably, the material of described column silk screen is polylactic acid PLA, polycaprolactone (PCL), PGA PGA or poly-to dioxy cyclohexanone PDO.
Preferably, the material of described barrier film is polylactic acid PLLA, Poly(D,L-lactide-co-glycolide PLGA or polycaprolactone (PCL).
Preferably, described suture is dioxy cyclohexanone PDO material.
Preferably, described barrier film is provided with 3 ~ 5 layers.
As mentioned above, a kind of degradable stopper of this utility model, has following beneficial effect:
This utility model can be absorbed by the body completing shutoff defect Post operation, eliminates stopper and remains in human body the hidden danger causing side effect; This utility model effectively prevent the untoward reaction such as human body nickel allergy, thrombosis, acute myocardial infarction that stopper causes in vivo simultaneously.
Accompanying drawing explanation
Fig. 1 is the first embodiment schematic diagram of the present utility model.
Fig. 2 is the second embodiment schematic diagram of the present utility model.
Fig. 3 is the third embodiment schematic diagram of the present utility model.
Fig. 4 is the 4th kind of embodiment schematic diagram of the present utility model.
Fig. 5 is the direction view of card of the present utility model.
In figure: 1 column silk screen
11 left sides
12 right sides
2 suspension ring
3 barrier films
Detailed description of the invention
The structure that Figure of description illustrates, ratio, size etc., content all only in order to coordinate description to disclose, understand for person skilled in the art scholar and read, and be not used to limit the enforceable qualifications of this utility model, therefore the not technical essential meaning of tool, the adjustment of the modification of any structure, the change of proportionate relationship or size, do not affecting under effect that this utility model can produce and the object that can reach, all should still drop in scope that technology contents that this utility model discloses can contain.Simultaneously, quote in this description as " on ", D score, "front", "rear", the term such as " centre ", also only for ease of understanding of describing, and be not used to limit the enforceable scope of this utility model, the change of its relativeness or adjustment, under changing technology contents without essence, when being also considered as the enforceable category of this utility model.
Be the different embodiments of the degradable stopper of this utility model as Figure 1-Figure 4, Fig. 5 is end plate facing view of the present utility model, and embodiment of the present utility model is not limited to the above-mentioned embodiment enumerated.
This utility model comprises the column silk screen 1 of the hollow made by degradation material, the two ends of described column silk screen 1 are provided with left side 11 and right side 12, one is had at least to form card along edge outwardly convex in described two end faces, as shown in Figure 1 and Figure 4, stopper has a card, as shown in Figures 2 and 3, stopper has two cards.The twine of described column silk screen 1 collects formation one node respectively on left side 11 and right side 12, and described node fuses together and formed adding man-hour many calcaneus retes silk, one of them node is connected with the suspension ring 2 made by degradation material.Be provided with barrier film 3 in described column silk screen 1, described barrier film 3 is sewn in column silk screen 1 by degradable suture, and described barrier film 3 is degradation material; Also developing materials are provided with in described stopper.
In the present embodiment, the developing powder added in column silk screen 1 when described developing materials are metal or the production of the good biocompatibility be coated in barrier film 3.If in barrier film 3 metal material of coated good biocompatibility, then metal material can be the metal such as tantalum, platinum; If the developing powder added in column silk screen 1 when producing, so developing powder can be BaCO
3deng, the developing powder amount added should account for about 5% of column silk screen 1 gross mass, and such stopper entirety will produce developability.Developing materials will with angiography machine or ultrasonic device with the use of the position carrying out auxiliary examination stopper, the principle of this equipment is: atomic weight is larger, the thing that density is larger, more X-ray can be blocked, stain or a profile can be gone out in the position display be blocked thus, thus make doctor can see the situation of stopper over the display.
In the present embodiment, the material of described column silk screen 1 is polylactic acid PLA, polycaprolactone (PCL), PGA PGA or poly-to degradation materials such as dioxy cyclohexanone PDO.
In the present embodiment, the material of described barrier film 3 is the degradation materials such as polylactic acid PLLA, Poly(D,L-lactide-co-glycolide PLGA or polycaprolactone (PCL).
In the present embodiment, in order to ensure plugging effect, described barrier film 3 is provided with 3 ~ 5 layers.
Described suture is the degradation materials such as dioxy cyclohexanone PDO material in the present embodiment, and in addition, in the present embodiment, suspension ring 2 can have multiple with the connected mode of node, such as, punch on node, are then connected with node through hole by suspension ring; Or direct fusion with node by suspension ring 2 is connected.
Suspension ring 2 in this utility model play the effect of conveying stopper, use Medical foreign body forceps clamping suspension ring 2 that stopper is delivered to lesion locations during work.
The using method of this utility model in intervene operation is: first operate at the correct position of patient body, from knife-edge part, guide sheath pipe is stretched into diseased region; Then Medical foreign body forceps is clamped suspension ring 2, and insert guide sheath pipe from one end human body of guide sheath pipe and then deliver to lesion locations, before not delivering to lesion locations, stopper is the strip do not strutted; According to the developing materials display on stopper, doctor can detect the position of stopper at any time, can adjust in time if pinpointed the problems; When stopper can strut gradually after one end human body of guide sheath pipe is deviate from, the ductus arteriosus occluder after strutting is at diseased region; After stopper is deviate from completely from guide sheath pipe, control foreign body forceps and unclamp suspension ring 2, and foreign body forceps has been withdrawn from the installation of stopper together with guide sheath pipe in human body.After a period of time has passed, when automatically degrading by stopper after tissue reparation.
In sum, a kind of degradable stopper of this utility model, can solve after stopper is finished the work and the problems such as stopper comes off, thrombosis, valve damage occur.So this utility model effectively overcomes practical problems more of the prior art thus has very high value and use meaning.
Above-mentioned embodiment is illustrative principle of the present utility model and effect thereof only, but not for limiting this utility model.This utility model also has many aspects can improve under the prerequisite of overall thought, all without prejudice under spirit of the present utility model and category, can modify above-described embodiment or change for person skilled in the art scholar.Therefore, such as have in art and usually know that the knowledgeable modifies or changes not departing from all equivalences completed under the spirit and technological thought that this utility model discloses, must be contained by claim of the present utility model.
Claims (6)
1. a degradable stopper, it is characterized in that: the column silk screen (1) comprising the hollow made by degradation material, the two ends of described column silk screen (1) are left side (11) and right side (12), one is had at least to form card along edge outwardly convex in described two end faces, the twine of described column silk screen (1) collects formation one node respectively on left side (11) and right side (12), one of them node is connected with the suspension ring (2) made by degradation material, barrier film (3) is provided with in described column silk screen (1), described barrier film (3) is sewn in column silk screen (1) by degradable suture, described barrier film (3) is degradation material, also developing materials are provided with in described stopper.
2. the degradable stopper of one according to claim 1, is characterized in that: the developing powder added in column silk screen (1) when described developing materials are metal or the production of the good biocompatibility be coated in barrier film (3).
3. the degradable stopper of one according to claim 1, is characterized in that: the material of described column silk screen (1) is polylactic acid PLA, polycaprolactone (PCL), PGA PGA or poly-to dioxy cyclohexanone PDO.
4. the degradable stopper of one according to claim 1, is characterized in that: the material of described barrier film (3) is polylactic acid PLLA, Poly(D,L-lactide-co-glycolide PLGA or polycaprolactone (PCL).
5. the degradable stopper of one according to claim 1, is characterized in that: described suture is dioxy cyclohexanone PDO material.
6. the degradable stopper of one according to claim 1, is characterized in that: described barrier film (3) is provided with 3 ~ 5 layers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420317506.0U CN204016366U (en) | 2014-06-13 | 2014-06-13 | A kind of degradable stopper |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420317506.0U CN204016366U (en) | 2014-06-13 | 2014-06-13 | A kind of degradable stopper |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204016366U true CN204016366U (en) | 2014-12-17 |
Family
ID=52056293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201420317506.0U Expired - Lifetime CN204016366U (en) | 2014-06-13 | 2014-06-13 | A kind of degradable stopper |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN204016366U (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017113532A1 (en) * | 2015-12-31 | 2017-07-06 | 常州锦葵医疗器械有限公司 | Imageable and degradable occluder |
| WO2017113531A1 (en) * | 2015-12-31 | 2017-07-06 | 常州锦葵医疗器械有限公司 | Degradable occluder |
| CN107510481A (en) * | 2017-09-18 | 2017-12-26 | 广州派若弥医疗器械有限公司 | Skull base defects block repair apparatus |
| CN108273142A (en) * | 2018-03-21 | 2018-07-13 | 上海形状记忆合金材料有限公司 | A kind of preparation method of the controllable degradable plugging device of degradation rate |
| CN110522485A (en) * | 2019-08-27 | 2019-12-03 | 浙江大学 | A kind of complete turn of tidal stream bracket of degradable enteron aisle |
| CN111110399A (en) * | 2019-12-09 | 2020-05-08 | 先健科技(深圳)有限公司 | Implantable device |
| CN111281462A (en) * | 2019-04-29 | 2020-06-16 | 上海锦葵医疗器械股份有限公司 | Plugging device with two ends without outwards protruding point structures |
| CN112914661A (en) * | 2021-02-01 | 2021-06-08 | 上海锦葵医疗器械股份有限公司 | Degradable heart left auricle occluder and manufacturing method thereof |
-
2014
- 2014-06-13 CN CN201420317506.0U patent/CN204016366U/en not_active Expired - Lifetime
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017113532A1 (en) * | 2015-12-31 | 2017-07-06 | 常州锦葵医疗器械有限公司 | Imageable and degradable occluder |
| WO2017113531A1 (en) * | 2015-12-31 | 2017-07-06 | 常州锦葵医疗器械有限公司 | Degradable occluder |
| US11337683B2 (en) | 2015-12-31 | 2022-05-24 | Mallow Medical (Shanghai) Co., Ltd. | Degradable occluder |
| CN107510481A (en) * | 2017-09-18 | 2017-12-26 | 广州派若弥医疗器械有限公司 | Skull base defects block repair apparatus |
| CN108273142A (en) * | 2018-03-21 | 2018-07-13 | 上海形状记忆合金材料有限公司 | A kind of preparation method of the controllable degradable plugging device of degradation rate |
| CN108273142B (en) * | 2018-03-21 | 2021-01-12 | 上海形状记忆合金材料有限公司 | Preparation method of degradable occluder with controllable degradation rate |
| CN111281462A (en) * | 2019-04-29 | 2020-06-16 | 上海锦葵医疗器械股份有限公司 | Plugging device with two ends without outwards protruding point structures |
| CN110522485A (en) * | 2019-08-27 | 2019-12-03 | 浙江大学 | A kind of complete turn of tidal stream bracket of degradable enteron aisle |
| CN110522485B (en) * | 2019-08-27 | 2020-12-11 | 浙江大学 | Degradable intestinal tract complete diversion bracket |
| CN111110399A (en) * | 2019-12-09 | 2020-05-08 | 先健科技(深圳)有限公司 | Implantable device |
| CN112914661A (en) * | 2021-02-01 | 2021-06-08 | 上海锦葵医疗器械股份有限公司 | Degradable heart left auricle occluder and manufacturing method thereof |
| CN112914661B (en) * | 2021-02-01 | 2022-08-30 | 上海锦葵医疗器械股份有限公司 | Degradable heart left auricle occluder and manufacturing method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN204016366U (en) | A kind of degradable stopper | |
| CN106456183B (en) | Locking device | |
| Thanopoulos et al. | Transcatheter closure of perimembranous ventricular septal defects in infants and children using the Amplatzer perimembranous ventricular septal defect occluder | |
| Bissessor | Current perspectives in percutaneous atrial septal defect closure devices | |
| Yu et al. | Mechanical antithrombotic intervention by LAA occlusion in atrial fibrillation | |
| CN205251616U (en) | Can absorb plugging device | |
| Thanopoulos et al. | Catheter closure of atrial septal defects using the Cocoon septal occluder: preliminary results of a European multicenter study | |
| Szkutnik et al. | Transcatheter closure of double atrial septal defects with a single Amplatzer device | |
| CN110313945A (en) | A kind of plugging device and preparation method thereof | |
| Gu et al. | Transcatheter device closure of intracristal ventricular septal defects | |
| CN108451570A (en) | Assist molding device and method in Wholly-degradable plugging device body | |
| Li et al. | Initial experiences with a novel biodegradable device for percutaneous closure of atrial septal defects: from preclinical study to first‐in‐human experience | |
| Baspinar et al. | Bioabsorbable atrial septal occluder for percutaneous closure of atrial septal defect in children | |
| WO2020093925A1 (en) | Occluder | |
| Xie et al. | A novel-design poly-L-lactic acid biodegradable device for closure of atrial septal defect: long-term results in swine | |
| Li et al. | Initial Clinical Experience with the Biodegradable AbsnowTM Device for Percutaneous Closure of Atrial Septal Defect: A 3‐Year Follow‐Up | |
| Pavcnik et al. | Double BioDisk: a new bioprosthetic device for transcatheter closure of atrial septal defects-a feasibility study in adult sheep | |
| Verzini et al. | Carotid artery stenting: technical issues and role of operators' experience | |
| Palacios et al. | Structural heart intervention. Beyond transcatheter valve therapy | |
| CN204971378U (en) | Plugging device that can degrade completely in vivo | |
| CN209611204U (en) | Plugging device | |
| Du et al. | A prospective, single-center, phase I clinical trial to evaluate the value of transesophageal echocardiography in the closure of patent foramen ovale with a novel biodegradable occluder | |
| Mahmoud et al. | Cocoon devices for transcatheter closure of atrial septal defect and patent ductus arteriosus in children: single center experience | |
| Malzahn et al. | Transcatheter closure of large atrial septal defects in adults | |
| Testa et al. | Patent foramen ovale occlusion with the Cocoon PFO Occluder. The PROS-IT collaborative project |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20141217 |
|
| CX01 | Expiry of patent term |